Blade Q2 revenue $61M (+71%), medical $34.4M (+99%), net loss $12.2M

Strata Critical Medical, Inc.

2023-Q2 EPS reported -$0.31 revenue$106,260,000

Q2 revenue $61.0M (+71% YoY); medical revenue $34.4M (+99% YoY, +29% sequentially).
Flight Profit $10.4M (+103% YoY); Flight Margin 17.0% vs 14.3%.
GAAP net loss $12.2M vs net income $8.4M in prior-year quarter.
Adjusted EBITDA -$4.4M vs -$6.1M, improved 27%; Medical Adj. EBITDA $3.0M.
Short Distance revenue up 75% YoY, driven by Blade Europe acquisition and organic growth.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Strata Critical Medical, Inc. reported second quarter ended June 30, 2023 results: revenue $61.0 million, net income $(12,232).

Period: second quarter ended June 30, 2023
Revenue: $61.0 million
Net income: $(12,232)
Result: reported results

Exact text from the filing

9, 2023 Blade Air Mobility Reports Financial Results for the Second Quarter Ended June 30, 2023 • Second quarter ended June 30, 2023 revenue up 71% versus the prior year to $61.0 million • Medical revenue of $34.4 million in Q2 2023 up 99% versus the prior year period, up 29% sequentially versus Q1 2023 • Short Distance revenue up 75% in Q2 2023 versus the prior

View on SEC.gov

Browse all earnings releases →

Strata Critical Medical, Inc. filing history →

Source: SEC EDGAR

accession 0001779128-23-000075

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.